BEAM Beam Therapeutics Inc
Company Analysis
Latest News
Beam Therapeutics Inc Q2 2026 Earnings Preview: What Analysts Expect on August 04, 2026
For the second quarter of 2026, analysts anticipate Beam Therapeutics will report revenue of $315.40 million and earnings per share of $1.00, while the current...
🔴 Beam Therapeutics is trading 4.1% down today amid broader biotech sector weakness
Beam Therapeutics is trading 4.1% down at $25.40 amid a sharp pullback in biotechnology stocks. • The move appears tied to broader sector weakness, as the...
🟢 Beam Therapeutics is trading 4.2% up today on broader risk-on sentiment and easing macro tensions
Beam Therapeutics is trading at $26.11 (+4.15%) as broader risk-on sentiment and easing macroeconomic tensions support a rotation back into growth assets. •...
🟢 Beam Therapeutics is trading 4.4% up today on broader risk-on sentiment and easing macro tensions
Beam Therapeutics is trading at $26.20 (4.4%) up today, rebounding from last week's biotech sector weakness as broader market sentiment improves. • The stock...
Beam Therapeutics to Present BEAM-302 Data for Alpha-1 Antitrypsin Deficiency
Beam Therapeutics will present updated Phase 1/2 clinical data for BEAM-302, its lead program for alpha-1 antitrypsin deficiency (AATD). The oral presentation...
🟢 Beam Therapeutics is trading 4% up today after snapping an eight-session slide
Beam Therapeutics is trading 4% up today at $27.39 as the stock stages a technical bounce following an extended period of selling pressure. • Shares are...
🔴 Beam Therapeutics is trading 4% down today as profit-taking extends multi-day slide
Beam Therapeutics is trading 4% down at $26.42 as profit-taking and fading momentum continue to weigh on the stock during an extended pullback. • The decline...
🟢 Beam Therapeutics is trading 4.5% up today on a technical rebound following sector weakness
Beam Therapeutics is trading at $32.40 (+4.52%) in pre-market as the stock stages a technical rebound following a period of broader biotech sector weakness. •...
🔴 Beam Therapeutics is trading 4.1% down today as biotech sector sell-off continues
Beam Therapeutics is trading 4.1% down at $31.33 as the broader biotech sector faces pressure from profit-taking and risk-off sentiment. • The decline...
🔴 Beam Therapeutics is trading 10.0% down
Beam Therapeutics is trading at $32.22, down 10.0% from a comparison close of $35.82 during regular trading. This is a price-action follow-up, so a separate...
🔴 Beam Therapeutics is trading 5.2% down today following arbitration loss to Prime Medicine
Beam Therapeutics is trading 5.2% down at $33.97 today, primarily impacted by an arbitration tribunal's decision in favor of Prime Medicine regarding their...
🟢 Beam Therapeutics is trading 4.11% up today following FDA clearance for BEAM-304 and positive clinical data
Beam Therapeutics is trading at $37.29 (+4.11%) following recent FDA clearance for BEAM-304 and positive clinical data for BEAM-302. • The company recently...
🔴 BEAM is trading 5.8% down today as investors react to arbitration resolution and profit-taking
• BEAM is trading at $35.71 (-5.83%) as the stock pulls back following a significant rally driven by positive clinical data. • The decline follows a sharp...
🔴 BEAM is trading 4% down today on profit-taking after its BEAM-302 data rally
BEAM is trading 4% down at $36.40 as the stock undergoes a pre-market pullback following a sharp rally driven by positive clinical results. • The recent gains...
🟢 BEAM is trading 4.5% up today on positive Phase 1/2 data for its BEAM-302 program
BEAM is trading 4.5% up at $36.91 after investors reacted positively to new Phase 1/2 data for its BEAM-302 base-editing program in alpha-1 antitrypsin...
🟢 BEAM is trading 4.4% up today after promising BEAM-302 clinical data and broader biotech gains
BEAM is trading at $36.87 (4.39% up) after reporting promising Phase 1/2 clinical data for its BEAM-302 gene-editing program. • The study demonstrated...
🟢 BEAM extends move to 5.3% up
BEAM is trading at $35.26, up 5.3% versus the comparison close of $33.48 during regular trading. This is a price-movement alert; no separate company-specific...
🟢 BEAM is trading 4.2% up today with no clear company-specific catalyst
BEAM is trading 4.2% up now at $34.87 after a recent multi-day pullback and sector-driven weakness. There are no fresh company-specific headlines, earnings, or...
🔴 BEAM is trading 4.02% down today amid broader biotech weakness and technical mean reversion
BEAM is trading at $32.94 (down 4.02%) as the stock continues its recent pullback amid a broader risk-off tone in the biotech sector and a slightly lower...
🟢 BEAM is trading 4.3% up today as it recovers from its recent pullback
BEAM is trading at $35.80 (+4.31%) after hours, reversing part of its June 30 pullback despite no major company-specific announcements, earnings releases, or...